Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 23, 2015 11:16 AM ET

Biotechnology

Company Overview of CoLucid Pharmaceuticals, Inc.

Company Overview

CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecule for the acute treatment of migraine headaches. Its lead product candidate is Lasmiditan, an oral tablet that is in a Phase III clinical program for the acute treatment of migraine headaches in adults. The company also develops IV lasmiditan, which is Phase II clinical trial for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. CoLucid Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Burlington, Massachusetts.

15 New England Executive Park

Burlington, MA 01803

United States

Founded in 2005

5 Employees

Phone:

781-365-2596

Key Executives for CoLucid Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 48
Total Annual Compensation: $271.7K
Vice President of Business Development
Age: 62
Total Annual Compensation: $120.0K
Vice President of Research & Development
Age: 55
Total Annual Compensation: $221.9K
Vice President of Clinical and Regulatory Operations
Age: 55
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2014.

CoLucid Pharmaceuticals, Inc. Key Developments

CoLucid Pharmaceuticals, Inc.(NasdaqGM:CLCD) added to NASDAQ Composite Index

CoLucid Pharmaceuticals, Inc. has been added to Nasdaq Composite Index.

CoLucid Pharmaceuticals Announces Initiation of First Phase 3 Pivotal Trial of Lasmiditan in Migraine

CoLucid Pharmaceuticals, Inc. announced that the first patient has been randomized in its SAMURAI study, the company's first Phase 3 pivotal trial of lasmiditan. The objective of SAMURAI is to evaluate the safety and efficacy of lasmiditan (100 mg and 200 mg) in comparison to placebo two hours after dosing on freedom from migraine headache pain, which is primary endpoint, and on freedom from the most bothersome associated symptom of migraine (nausea, phonophobia or photophobia), which is secondary endpoint. SAMURAI is a randomized, double-blind, placebo-controlled parallel group study. The study is expected to treat up to 1,483 migraine patients with lasmiditan at approximately 70 U.S. sites for approximately 12 months. SAMURAI is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.

CoLucid Pharmaceuticals, Inc. Announces Relocation of Headquarters to Massachusetts

CoLucid Pharmaceuticals, Inc. announced the relocation of its corporate headquarters to Massachusetts. The company is currently operating in Burlington while it searches for office space in the Cambridge area.

Similar Private Companies By Industry

Company Name Region
Avecia Biotechnology, Inc. United States
Imiplex LLC United States
Icon Genetics, Inc. United States
Kytogenics Pharmaceutical, Inc. United States
ApoVax, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 12, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CoLucid Pharmaceuticals, Inc., please visit www.colucid.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.